Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine sulfate liposome (Talon Therapeutics, 0432b3)
- Development stage
- Unknown
- Lead developer
- Assertio
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal vincristine is a nanoparticle-encapsulated formulation of the vinca alkaloid vincristine sulfate. The liposomal delivery system, specifically a sphingomyelin and cholesterol-based vesicle, is designed to prolong the circulation time of vincristine and increase its accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect. Mechanistically, vincristine binds to tubulin, inhibiting the assembly of microtubules and causing mitotic arrest in the metaphase of the cell cycle, ultimately leading to apoptosis. This formulation was developed to overcome the dose-limiting neurotoxicity and rapid clearance associated with conventional vincristine. It received FDA accelerated approval (as Marqibo) for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
- Brand names
- Marqibo
- Other names
- liposomal vincristinevincristine sulfate liposome injection
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vincristine sulfate liposome (Talon Therapeutics, 0432b3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine sulfate liposome (Talon Therapeutics, 0432b3).